ArticleAnnals of the rheumatic diseases2018
Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis.
Article in Annals of the rheumatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 57 citations in OpenAlex.
- Outcome of Patients With Lupus Nephritis Treated With an Anti-CD40 Monoclonal Antibody According to Kidney Biopsy Features.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- Integrative bioinformatics and experimental analysis reveals FRA1 as a key mediator of tubulointerstitial inflammation in lupus nephritis.Molecular medicine reports · 2026Article
- M-CSF, inducing CD163 macrophages, is associated with severity and prognosis of glomerulonephritis in microscopic polyangiitis.Arthritis research & therapy · 2025Article
- Determining IFI44 as a key lupus nephritis's biomarker through bioinformatics and immunohistochemistry.Renal failure · 2025Article
- LATS2 degradation promoted fibrosis damage and rescued by vitamin K3 in lupus nephritis.Arthritis research & therapy · 2024Article
- p16Lupus science & medicine · 2023Article
- Involvement of Epithelial-Mesenchymal Transition (EMT) in Autoimmune Diseases.International journal of molecular sciences · 2023Review
- Plasma Exosomal Non-Coding RNA Profile Associated with Renal Damage Reveals Potential Therapeutic Targets in Lupus Nephritis.International journal of molecular sciences · 2023Article
- Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis.Annals of the rheumatic diseases · 2022Article
- Transcriptome Studies in Lupus Nephritis.Archivum immunologiae et therapiae experimentalis · 2022Review
- New Treatment Options in Lupus Nephritis.Archivum immunologiae et therapiae experimentalis · 2022Review
- High p16RMD open · 2021Article
- Kidney Tertiary Lymphoid Structures in Lupus Nephritis Develop into Large Interconnected Networks and Resemble Lymph Nodes in Gene Signature.The American journal of pathology · 2020Article
- Proteomic analysis in lupus mice identifies Coronin-1A as a potential biomarker for lupus nephritis.Arthritis research & therapy · 2020Article
- An Update on the Diagnosis and Management of Lupus Nephritis.Current rheumatology reports · 2020Review
- Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis.Lupus · 2020Article
- Machine Learning to QuantifyFrontiers in immunology · 2020Article
- The role of Stim1 in the progression of lupus nephritis in mice.International journal of clinical and experimental pathology · 2020Article
- Prediction of prognosis and renal outcome in lupus nephritis.Lupus science & medicine · 2020Review
- Immune cell infiltration characteristics and related core genes in lupus nephritis: results from bioinformatic analysis.BMC immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesChronic renal impairment remains a feared complication of lupus nephritis (LN). The present work aimed at identifying mechanisms and markers of disease severity in renal tissue samples from patients with LN.
methodsWe performed high-throughput transcriptomic studies (Illumina HumanHT-12 v4 Expression BeadChip) on archived kidney biopsies from 32 patients with LN and eight controls (pretransplant donors). Histological staging (glomerular and tubular scores) and immunohistochemistry experiments were performed on the same and on a replication set of 37 LN kidney biopsy samples.
resultsA group of LN samples was identified by unsupervised clustering studies based on their gene expression features, that is, the overexpression of transcripts involved in antigen presentation, T and B cell activation. These samples were characterised by a significantly lower estimated glomerular filtration rate (eGFR) at the time of biopsy (T0) compared with the other systemic lupus erythematosus samples. Yet, apparent disease duration at T0, double-stranded DNA antibody titres at T0 and other relevant characteristics (serum C3, proteinuria, histological scores, numbers of previous flares) were not different between groups.Immunohistochemistry studies confirmed the association between interstitial infiltration by adaptive immune effectors and decreased renal function in the same and in a replication group of LN kidney biopsies. This was associated with transcriptomic, histological and immunohistochemical evidence of renal tubular cell involvement.
conclusionInterstitial infiltration of LN kidney biopsies by adaptive immune effectors is associated with impaired renal tubular cell function and decreased eGFR. These results open new perspectives in evaluating and treating patients with LN, focusing on intrarenal mechanisms of immune cell activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.